119 related articles for article (PubMed ID: 1687729)
1. Toward a chronotherapy of ovarian cancer with taxol. Part I: Basic background.
Cornélissen G; Halberg E; Long HJ; Prem K; Bakken E; Touitou Y; Elg S; Haus E; Halberg F
Chronobiologia; 1991; 18(4):153-66. PubMed ID: 1687729
[No Abstract] [Full Text] [Related]
2. Toward a chronotherapy of ovarian cancer with taxol. Part II: Test pilot study on circulating CA125.
Halberg E; Long HJ; Cornélissen G; Blank MA; Elg S; Touitou Y; Bakken E; Delmore P; Haus E; Sackett-Lundeen L
Chronobiologia; 1992; 19(1-2):17-42. PubMed ID: 1352750
[No Abstract] [Full Text] [Related]
3. Toward a chronotherapy of ovarian cancer. Part III: Salivary CA125 for chronochemotherapy by efficacy.
Cornélissen G; Halberg F; Halberg E; Bingham C; Haus E; Bast RC; Fujii S; Long HJ; Halberg F; Tamura K
Chronobiologia; 1992; 19(3-4):131-49. PubMed ID: 1362146
[No Abstract] [Full Text] [Related]
4. [Taxol and ovarian adenocarcinomas].
Marty M; Extra JM; Culine S; Rousseau F
Pathol Biol (Paris); 1992 Nov; 39(9):834-5. PubMed ID: 1347165
[No Abstract] [Full Text] [Related]
5. Power of chronobiologic pilots: a statistician's opinion.
Berry DA
Chronobiologia; 1993; 20(3-4):213-8. PubMed ID: 8131670
[No Abstract] [Full Text] [Related]
6. Salvage weekly paclitaxel in recurrent ovarian cancer.
Abu-Rustum NR; Aghajanian C; Barakat RR; Fennelly D; Shapiro F; Spriggs D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-62-S15-67. PubMed ID: 9346225
[TBL] [Abstract][Full Text] [Related]
7. Marker rhythmometry with macrophage-colony stimulating factor (M-CSF).
Elg S; Halberg E; Ramakrishnan S; Cornélissen G; Haus E; Nicolau G; Carson L; Twiggs L; Long HJ; Halberg F
Chronobiologia; 1991; 18(4):141-52. PubMed ID: 1687728
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal paclitaxel in the management of ovarian cancer.
Markman M
Semin Oncol; 1995 Oct; 22(5 Suppl 12):86-7. PubMed ID: 7481868
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel in platinum-resistant ovarian cancer patients. Argentine Multicenter Taxol Group.
Ezcurdia L; Jovtis SL; Mickiewicz E; Temperley G; Rondinón M; Blajman C; Cóppola FS; Lewi D; Cazap E; Breier S; Fasce H; Fein L; Polera J; Triguboff E; Uranga G; Pasccón G; Luchina AM; Martínez CA; Politi PM; Rubio G; Alvarez AM
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-53-S15-56. PubMed ID: 9346223
[TBL] [Abstract][Full Text] [Related]
10. Antineoplastic activity of two taxol derivatives on an ovarian tumor xenografted into nude mice.
Riondel J; Jacrot M; Nissou MF; Picot F; Bériel H; Mouriquand C; Potier P
Anticancer Res; 1988; 8(3):387-90. PubMed ID: 2898915
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of taxol given as a 3-hour infusion every 21 days.
Kris MG; O'Connell JP; Gralla RJ; Wertheim MS; Parente RM; Schiff PB; Young CW
Cancer Treat Rep; 1986 May; 70(5):605-7. PubMed ID: 2871928
[TBL] [Abstract][Full Text] [Related]
12. Vitamin A intoxication during taxol therapy for refractory ovarian cancer.
Muggia FM
J Natl Cancer Inst; 1992 Sep; 84(18):1444-5. PubMed ID: 1355115
[No Abstract] [Full Text] [Related]
13. [Taxol (paclitaxel) as second-line therapy in breast and ovarian cancer].
Borovik R; Steiner M; Atad J; Sneiderman B; Rosenberg T; Palti S
Harefuah; 1998 Apr; 134(8):605-8, 671. PubMed ID: 10911422
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
15. Weekly paclitaxel in the management of ovarian cancer.
Markman M
Semin Oncol; 2000 Jun; 27(3 Suppl 7):37-40. PubMed ID: 10952125
[TBL] [Abstract][Full Text] [Related]
16. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
[TBL] [Abstract][Full Text] [Related]
17. [Feasibility, activity, and change in the level of blood paclitaxel concentration after weekly paclitaxel therapy for a patient with recurrent ovarian cancer].
Ishioka S; Sagae S; Kudo R
Gan To Kagaku Ryoho; 2001 Jul; 28(7):1017-21. PubMed ID: 11478132
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacodynamic study of taxol in refractory acute leukemias.
Rowinsky EK; Burke PJ; Karp JE; Tucker RW; Ettinger DS; Donehower RC
Cancer Res; 1989 Aug; 49(16):4640-7. PubMed ID: 2568175
[TBL] [Abstract][Full Text] [Related]
19. Treatment with paclitaxel alone rather than combination with paclitaxel and cisplatin may be selective for cisplatin-resistant ovarian carcinoma.
Yamamoto K; Kikuchi Y; Kudoh K; Hirata J; Kita T; Nagata I
Jpn J Clin Oncol; 2000 Oct; 30(10):446-9. PubMed ID: 11185891
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
